Sptember 4, 2025 Company Name: AnGes Inc.
Presentative: Ei Yamada, President & CEO
We hereby announce that our subsidiary, EmendoBio Inc. ("EmendoBio"), has agreed to expand the scope of the license agreement previously disclosed in the notice dated March 14, 2024, titled "Notice of Conclusion of License Agreement and Revision of Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2024."
Under the original agreement, EmendoBio granted Anocca AB ("Anocca"), a Swedish biotechnology company, non-exclusive rights to use its proprietary OMNI-A4 nuclease, which was independently developed to address the challenge of off-target effects in genome editing-where DNA may be unintentionally cleaved at sites other than the intended target.
Anocca is currently utilizing OMNI-A4 in the development of TCR-T cell therapies targeting solid tumors. With this expansion, Anocca will be able to further incorporate the OMNI nuclease into additional product development within its ongoing TCR-T cell therapy programs.
As part of the expanded agreement, EmendoBio will receive an additional upfront payment and may also be eligible to receive further milestone payments depending on future progress.
This expanded agreement remains a non-exclusive license, allowing EmendoBio to continue its licensing activities freely with other partners.
The expansion of this agreement is not expected to have any impact on the consolidated earnings forecast for the fiscal year ending December 2025.
Should any matters requiring disclosure arise in the future, we will promptly make an announcement.
For further details regarding this agreement, please refer to the attached document.
(Note)This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.
New York, USA, 3 September 2025 - EmendoBio Inc. (EmendoBio), an innovative gene editing company focused on the discovery and engineering of novel CRISPR nucleases for the development of gene edited therapeutics, today announced the expansion of its OMNI-A4™ non-exclusive licensing agreement with Anocca AB (Anocca), a leading clinical-stage T-cell immunotherapy company.
The expanded agreement builds upon the successful foundation established in March 2024, under which EmendoBio licensed its OMNI-A4™ nuclease to Anocca to accelerate the manufacture and development of Anocca's deep pipeline of TCR-T cell therapies for difficult-to-treat solid cancers. Under the terms of the new agreement, Anocca will expand the use of the OMNI-A4™ nuclease to knock-out and knock-in genes to further enhance its TCR-T product candidates.
"This expansion represents a significant milestone in our partnership with Anocca," said Ei Yamada, Chief Executive Officer at EmendoBio. "By broadening the scope of our collaboration, we are supporting Anocca's development of focused TCR-T cell therapies to address unmet patient needs."
"We are pleased to expand our collaboration with EmendoBio, enabling Anocca to deliver further innovative products from our deep TCR-T cell therapy pipeline" said Reagan Jarvis, Co-Founder and CEO at Anocca.
The financial details of the expanded agreement have not been disclosed.
About EmendoBioEmendoBio is a next-generation AI-based CRISPR gene editing company leveraging its proprietary technology to enable high precision gene editing, which is critical for the development of safe medical applications of genome editing. Driven by cutting-edge AI-based tools, novel gene editing strategies, and advanced protein engineering tools, EmendoBio's novel nuclease discovery platform broadens the targetable range of the genome, while its target-specific optimization platform enables highly precise editing with high efficiency.
EmendoBio's proprietary OMNI™ nucleases also are designed to reduce "off-target" effects, i.e., cleavage at locations other than the targeted genes. Achieving such pinpoint precision is a substantial challenge for genome editing therapies.
The capabilities of the OMNI™ technology platform, along with deep expertise in genomic medicine and protein engineering, provide EmendoBio with a unique advantage when addressing indications, including within hematology, cardiovascular, ophthalmology, oncology, and other disease areas.
View EmendoBio's service offerings at https://www.emendobio.com.
EmendoBio Inc.Noa Wertheimer noaw@emendobio.com